ABT has solid value right now

the_jetset · 2026-05-13T14:10:49+00:00

=== SUMMARY === - The post analyzes Abbott Laboratories (ABT), highlighting a compressed forward P/E of ~14, solid free cash flow per share (~$4.24), a 3% dividend yield, and ~11.5% organic growth. - The author’s thesis is that ABT is a value play with significant upside (4% to 55% total shareholder return) over a 3–5 year horizon, supported by recent insider purchases and the potential for multiple expansion to 19–20x earnings. - Quality assessment: This is well-researched DD. The author provides specific financial metrics, insider activity, and a clear valuation argument, though the debt from the Exact Sciences acquisition is noted as a risk. === SENTIMENT === BULLISH === TRADE IDEAS === ABT - LONG | confidence: 0.85 | sentiment: +0.70 Speaker: u/the_jetset Thesis: 1. THE FACT: The post cites a forward P/E of ~14 (compressed), FCF/share of $4.24, 3% dividend yield, ~0.75% buyback potential, 11.5% organic growth, and multiple insider purchases between $91–$108. 2. THE BRIDGE: This data suggests the market underestimates ABT’s intrinsic value. A reversion to a P/E of 19–20 would yield 35–43% price appreciation, plus dividends and buybacks, making the risk/reward asymmetric. 3. THE VERDICT: A long position in ABT offers a margin of safety with a downside floor near the current PE (~13–14) and upside from multiple expansion, organic growth, and shareholder returns. 4. RISKS: Higher debt from the Exact Sciences acquisition could pressure margins or delay deleveraging; a recession or regulatory headwind could compress organic growth; the compressed PE may persist if sentiment remains negative. Timeframe: long-term Key Points: - FCF/share ~$4.24, Fwd PE ~14 (compressed) - Insider buying by CEO, CFO, directors signals confidence - Dividend yield 3% + buybacks ~0.75% total return - Organic growth 11.5% supports earnings momentum - 3-5 year horizon with 4% to 55% return range

AI Summary

Summary

The post analyzes Abbott Laboratories (ABT), highlighting a compressed forward P/E of ~14, solid free cash flow per share (~$4.24), a 3% dividend yield, and ~11.5% organic growth.
The author’s thesis is that ABT is a value play with significant upside (4% to 55% total shareholder return) over a 3–5 year horizon, supported by recent insider purchases and the potential for multiple expansion to 19–20x earnings.
Quality assessment: This is well-researched DD. The author provides specific financial metrics, insider activity, and a clear valuation argument, though the debt from the Exact Sciences acquisition is noted as a risk.

Score 15

Comments 14

Upvote % 100%

▶ Full Post Text

Ideas

u/the_jetset Reddit r/ValueInvesting

The post cites a forward P/E of ~14 (compressed), FCF/share of $4.24, 3% dividend yield, ~0.75% buyback potential, 11.5% organic growth, and multiple insider purchases between $91–$108. This data suggests the market underestimates ABT’s intrinsic value. A reversion to a P/E of 19–20 would yield 35–43% price appreciation, plus dividends and buybacks, making the risk/reward asymmetric. A long position in ABT offers a margin of safety with a downside floor near the current PE (~13–14) and upside from multiple expansion, organic growth, and shareholder returns. Higher debt from the Exact Sciences acquisition could pressure margins or delay deleveraging; a recession or regulatory headwind could compress organic growth; the compressed PE may persist if sentiment remains negative.

Summary

▶ Full Post Text

Ideas

More from Reddit — r/ValueInvesting